BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
水曜日, 9 23

Viridian Therapeutics Inc

VRDNNASDAQ
Trade with Public
Trade with Public
$22.12
0.542.5%
近くで: Sep 22, 5:00 PM EST
$22.56
0.441.99%
時間外: 5:18 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Viridian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viridian Therapeutics (VRDN).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy
14Buy
2Hold
Consensus RatingBuy# Analysts17Avg. Consensus PT$37Upside to Avg. PT+65.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 22, 2026RBC CapitalLisa WalterPT RaiseOutperform$36→$38
Aug 7, 2026RBC CapitalLisa WalterPT RaiseOutperform$35→$36
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved